MST1R Agonists for IBD and PSC Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) are often ineffective and associated with significant side effects, and there is a need for new methods to address the underlying inflammatory processes and risk factors.
Innovation Solution
Administering an agonist of the MST1/MST1R pathway to patients, which involves detecting and targeting variants of the MST1 and MST1R genes associated with increased risk of developing IBD and PSC, to promote macrophage polarization and epithelial wound repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-inflammatory and immunosuppressive drugs are administered to treat IBD and PSC, then inflammation is suppressed, but treatment effectiveness is low and significant side effects occur
Solution Approach 1:
The patent changes the therapeutic parameter from general anti-inflammatory/immunosuppressive agents to specific MST1R pathway agonists. This targeted parameter change addresses the underlying pathogenic mechanism (MST1R signaling deficiency) rather than merely suppressing symptoms, thereby improving treatment effectiveness while reducing off-target side effects associated with broad immunosuppression
Solution Approach 2:
The patent introduces MST1R agonists as a specific mediator to restore defective MST1R signaling in patients with IBD and PSC. This intermediary approach targets the specific molecular pathway deficiency identified in the diseases, providing a more precise therapeutic mechanism compared to non-specific immunosuppressants
2Object-affected harmful factors
If surgical removal of intestine parts is performed for CD, then severe inflammation is removed, but patient quality of life deteriorates and recurrence occurs
Solution Approach 1:
The patent uses MST1R agonists as a molecular intermediary to treat the underlying cause of inflammation rather than removing affected tissue surgically. This approach preserves intestinal tissue and patient quality of life while addressing the root pathogenic mechanism through targeted pathway activation
Solution Approach 2:
The patent enables preliminary pharmacological intervention that can prevent or reduce the need for surgical removal of intestine. By activating MST1R signaling early in disease progression, the therapy may prevent severe inflammation and tissue damage that would otherwise require surgical resection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach potentially reduces the severity of symptoms and inhibits the development of IBD and PSC by enhancing MST1/MST1R signaling, offering a more effective treatment option with reduced side effects.
Implementation Method 1
MST1R functions as a tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand
Implementation Method 2
MST1/MST1R signaling drives macrophage polarization, cellular chemotaxis, and epithelial wound repair
Implementation Method 3
MST1/MST1R signaling drives macrophage polarization, cellular chemotaxis, and epithelial wound repair
Data Source
AI summary
Methods of treating patients having inflammatory bowel disease (IBD) or primary sclerosing cholangitis (PSC) are provided herein.